Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joan Sorich

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Anti-Cancer Drugs|May 17, 2006
Phase I trial of continuous infusion 9-aminocamptothecin in patients with advanced solid tumors: 21-day infusion is an active well-tolerated regimenSanjeev Sewak, Joan Sorich, James O'Leary
Clinical Journal of Oncology Nursing|June 24, 2004
Oxaliplatin: practical guidelines for administrationJoan Sorich, Beth Taubes, Allan Wagner, et al.
Anti-Cancer Drugs|January 25, 2003
A phase I study of paclitaxel, estramustine phosphate and vinorelbine (Pacl-E-Vin) in advanced malignancies: triple tubulin targetingSanjeev Sewak, Abraham Chachoua, Anne Hamilton, et al.
Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract|May 7, 2002
Neoadjuvant chemotherapy with CPT-11 and cisplatin downstages locally advanced gastric cancerElliot Newman, Stuart G Marcus, Milan Potmesil, et al.
Gynecologic Oncology|January 15, 2008
Tolerance and activity of oxaliplatin with protracted topotecan infusion in patients with previously treated ovarian cancer. A phase I studyHoward Hochster, Thomas T Chen, Janice M Lu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2005
Phase I study of combined pegylated liposomal doxorubicin with protracted daily topotecan for ovarian cancerDeepu Mirchandani, Howard Hochster, Anne Hamilton, et al.
Anti-Cancer Drugs|April 13, 2004
A phase I and pharmacokinetic study of docetaxel combined with Doxil (pegylated liposomal doxorubicin) without and with granulocyte colony stimulating factorAnna C Pavlick, Catherine Chodkiewicz, Leonard Liebes, et al.
Anti-Cancer Drugs|October 24, 2002
Phase I and pharmacologic study of i.p. 9-aminocamptothecin given as six fractions over 14 daysFranco M Muggia, Leonard Liebes, Maitreyee Hazarika, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 2004
Biweekly 72-hour 9-aminocamptothecin infusion as second-line therapy for ovarian carcinoma: phase II study of the New York Gynecologic Oncology Group and the Eastern Cooperative Oncology GroupHoward Hochster, Elizabeth R Plimack, Carolyn D Runowicz, et al.
Anti-Cancer Drugs|April 8, 2003
Phase I study of amifostine as a cytoprotector of the gemcitabine/cisplatin combination in patients with advanced solid malignanciesMissak Haigentz, Mimi Kim, Joan Sorich, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Anti-Cancer Drugs|May 17, 2006
Phase I trial of continuous infusion 9-aminocamptothecin in patients with advanced solid tumors: 21-day infusion is an active well-tolerated regimenSanjeev Sewak, Joan Sorich, James O'Leary
Clinical Journal of Oncology Nursing|June 24, 2004
Oxaliplatin: practical guidelines for administrationJoan Sorich, Beth Taubes, Allan Wagner, et al.
Anti-Cancer Drugs|January 25, 2003
A phase I study of paclitaxel, estramustine phosphate and vinorelbine (Pacl-E-Vin) in advanced malignancies: triple tubulin targetingSanjeev Sewak, Abraham Chachoua, Anne Hamilton, et al.
Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract|May 7, 2002
Neoadjuvant chemotherapy with CPT-11 and cisplatin downstages locally advanced gastric cancerElliot Newman, Stuart G Marcus, Milan Potmesil, et al.
Gynecologic Oncology|January 15, 2008
Tolerance and activity of oxaliplatin with protracted topotecan infusion in patients with previously treated ovarian cancer. A phase I studyHoward Hochster, Thomas T Chen, Janice M Lu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2005
Phase I study of combined pegylated liposomal doxorubicin with protracted daily topotecan for ovarian cancerDeepu Mirchandani, Howard Hochster, Anne Hamilton, et al.
Anti-Cancer Drugs|April 13, 2004
A phase I and pharmacokinetic study of docetaxel combined with Doxil (pegylated liposomal doxorubicin) without and with granulocyte colony stimulating factorAnna C Pavlick, Catherine Chodkiewicz, Leonard Liebes, et al.
Anti-Cancer Drugs|October 24, 2002
Phase I and pharmacologic study of i.p. 9-aminocamptothecin given as six fractions over 14 daysFranco M Muggia, Leonard Liebes, Maitreyee Hazarika, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 2004
Biweekly 72-hour 9-aminocamptothecin infusion as second-line therapy for ovarian carcinoma: phase II study of the New York Gynecologic Oncology Group and the Eastern Cooperative Oncology GroupHoward Hochster, Elizabeth R Plimack, Carolyn D Runowicz, et al.
Anti-Cancer Drugs|April 8, 2003
Phase I study of amifostine as a cytoprotector of the gemcitabine/cisplatin combination in patients with advanced solid malignanciesMissak Haigentz, Mimi Kim, Joan Sorich, et al.
Pageof 2